Bruce Car's Insider Trades & SAST Disclosures
Bruce Car's most recent trade in Enanta Pharmaceuticals Inc was a trade of 15,700 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bruce Car.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Lockheed Martin Corp. | Bruce A. Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 133 | 5,501 | - | - | Phantom Stock Units | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 112,000 | 112,000 | - | - | Stock Options (Right to buy) | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2025 | 19,000 | 19,000 | - | - | Restricted Share Unit Award | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 4,750 | 14,250 | - | - | Restricted Share Unit Award | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2025 | 4,750 | 7,133 | - | 0 | Common Shares | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.64 per share. | 05 Jan 2025 | 2,331 | 4,802 | - | 38.6 | 90,070 | Common Shares |
| RPM International, Inc. | Bruce A. Carbonari | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.11 per share. | 31 Oct 2024 | 396 | 7,019 (0%) | 0% | 127.1 | 50,336 | Common Stock, $0.01 par value |
| RPM International, Inc. | Bruce A. Carbonari | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 1,400 | 7,415 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 33.58 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | 33.6 | 1,007,490 | Common Shares |
| RPM International, Inc. | Bruce A. Carbonari | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jun 2024 | 9,779 | 22,519 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| RPM International, Inc. | Bruce A. Carbonari | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jun 2024 | 9,779 | 6,015 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 15,700 | 15,700 | - | - | Stock Option (right to buy) | |
| Lockheed Martin Corp. | A. Bruce Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 401 | 5,231 | - | - | Phantom Stock Units | |
| Biohaven Ltd | Car Bruce | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 96,250 | 96,250 | - | - | Stock Options (Right to buy) | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 78,750 | 78,750 | - | - | Stock Options (Right to buy) | |
| RPM International, Inc. | Bruce A. Carbonari | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.27 per share. | 31 Oct 2023 | 374 | 15,794 (0%) | 0% | 91.3 | 34,135 | Common Stock, $0.01 par value |
| RPM International, Inc. | Bruce A. Carbonari | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2023 | 1,800 | 16,168 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 10,800 | 10,800 | - | - | Stock Option (right to buy) | |
| Lockheed Martin Corp. | Bruce A. Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 353 | 4,701 | - | - | Phantom Stock Units | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 7,520 | 7,520 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 4,444 | 10,465 (0%) | 0% | 0 | Common Stock | |
| RPM International, Inc. | Bruce A. Carbonari | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.57 per share. | 31 Oct 2022 | 462 | 14,368 (0%) | 0% | 94.6 | 43,691 | Common Stock, $0.01 par value |
| RPM International, Inc. | Bruce A. Carbonari | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 1,900 | 14,830 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Biohaven Ltd | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 300,000 | 300,000 | - | - | Stock Options (Right to Buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2022 | 10,000 | 0 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.00 per share. | 12 Aug 2022 | 10,000 | 16,021 (0%) | 0% | 27 | 270,000 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 85.04 per share. | 12 Aug 2022 | 5,107 | 10,914 (0%) | 0% | 85.0 | 434,287 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 85.96 per share. | 12 Aug 2022 | 4,893 | 6,021 (0%) | 0% | 86.0 | 420,612 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.58 per share. | 21 Mar 2022 | 6,000 | 6,000 (0%) | 0% | 25.6 | 153,480 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 66.70 per share. | 21 Mar 2022 | 2,676 | 3,324 (0%) | 0% | 66.7 | 178,489 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 68.66 per share. | 21 Mar 2022 | 2,210 | 807 (0%) | 0% | 68.7 | 151,739 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 69.52 per share. | 21 Mar 2022 | 807 | 0 (0%) | 0% | 69.5 | 56,103 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 67.23 per share. | 21 Mar 2022 | 307 | 3,017 (0%) | 0% | 67.2 | 20,640 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 6,874 | 6,874 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 6,874 | 18,793 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 2,041 | 16,752 (0%) | 0% | 29.1 | 59,352 | Common stock |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 12,992 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 7,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 1,073 | 11,919 (0%) | 0% | 31.4 | 33,719 | Common stock |
| Lockheed Martin Corp. | Bruce A. Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 417 | 4,236 | - | - | Phantom Stock Units | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 3,688 | 3,688 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 2,546 | 6,021 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 3,437 | 10,530 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 3,437 | 3,437 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.58 per share. | 06 Jan 2022 | 1,205 | 9,325 (0%) | 0% | 32.6 | 39,259 | Common stock |
| RPM International, Inc. | Bruce A. Carbonari | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.20 per share. | 29 Oct 2021 | 396 | 12,425 (0%) | 0% | 87.2 | 34,531 | Common Stock, $0.01 par value |
| RPM International, Inc. | Bruce A. Carbonari | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2021 | 1,800 | 12,821 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Benchmark Electronics Inc. | Bruce A. Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 5,200 | 28,246 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.78 per share. | 05 Apr 2021 | 2,250 | 5,725 (0%) | 0% | 6.8 | 15,255 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 2,250 | 0 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 176.70 per share. | 05 Apr 2021 | 1,968 | 3,757 (0%) | 0% | 176.7 | 347,747 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 05 Apr 2021 | 282 | 3,475 (0%) | 0% | 180 | 50,760 | Common Stock |
| Enanta Pharmaceuticals Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 44,000 | 44,000 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Restricted stock units | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.78 per share. | 02 Feb 2021 | 2,250 | 5,725 (0%) | 0% | 6.8 | 15,255 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 2,250 | 2,250 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 190.50 per share. | 02 Feb 2021 | 1,732 | 3,993 (0%) | 0% | 190.5 | 329,948 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 192.32 per share. | 02 Feb 2021 | 300 | 3,693 (0%) | 0% | 192.3 | 57,695 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 194.38 per share. | 02 Feb 2021 | 218 | 3,475 (0%) | 0% | 194.4 | 42,375 | Common Stock |
| Lockheed Martin Corp. | Bruce A. Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 501 | 3,709 | - | - | Phantom Stock Units | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 2,155 | 2,155 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 1,475 | 3,475 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 3,437 | 6,874 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 3,437 | 8,284 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.09 per share. | 06 Jan 2021 | 1,191 | 7,093 (0%) | 0% | 44.1 | 52,506 | Common stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.78 per share. | 14 Dec 2020 | 2,250 | 4,250 (0%) | 0% | 6.8 | 15,255 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 2,250 | 4,500 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 247.63 per share. | 14 Dec 2020 | 710 | 2,358 (0%) | 0% | 247.6 | 175,817 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 244.97 per share. | 14 Dec 2020 | 589 | 3,325 (0%) | 0% | 245.0 | 144,287 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 248.27 per share. | 14 Dec 2020 | 357 | 2,001 (0%) | 0% | 248.3 | 88,634 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 244.05 per share. | 14 Dec 2020 | 287 | 3,914 (0%) | 0% | 244.0 | 70,041 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 246.27 per share. | 14 Dec 2020 | 257 | 3,068 (0%) | 0% | 246.3 | 63,292 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 240.94 per share. | 14 Dec 2020 | 49 | 4,201 (0%) | 0% | 240.9 | 11,806 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 249.00 per share. | 14 Dec 2020 | 1 | 2,000 (0%) | 0% | 249 | 249 | Common Stock |
| RPM International, Inc. | Bruce A. Carbonari | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.67 per share. | 30 Oct 2020 | 473 | 11,021 (0%) | 0% | 84.7 | 40,049 | Common Stock, $0.01 par value |
| RPM International, Inc. | Bruce A. Carbonari | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2020 | 1,700 | 11,494 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2020 | 2,250 | 6,750 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.78 per share. | 11 Aug 2020 | 2,250 | 4,250 (0%) | 0% | 6.8 | 15,255 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 125.78 per share. | 11 Aug 2020 | 1,300 | 2,950 (0%) | 0% | 125.8 | 163,512 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 126.71 per share. | 11 Aug 2020 | 740 | 2,210 (0%) | 0% | 126.7 | 93,767 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 127.58 per share. | 11 Aug 2020 | 110 | 2,100 (0%) | 0% | 127.6 | 14,034 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 131.16 per share. | 11 Aug 2020 | 100 | 2,000 (0%) | 0% | 131.2 | 13,116 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Sale of securities on an exchange or to another person at price $ 106.86 per share. | 18 May 2020 | 4,000 | 2,000 (0%) | 0% | 106.9 | 427,440 | Common Stock |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2020 | 4,000 | 9,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Bruce L.A. Carter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.78 per share. | 18 May 2020 | 4,000 | 6,000 (0%) | 0% | 6.8 | 27,120 | Common Stock |
| Benchmark Electronics Inc. | Bruce A. Carlson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 7,883 | 23,046 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2020 | 6,874 | 6,874 (0%) | 0% | - | Common stock | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2020 | 6,874 | 13,748 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.64 per share. | 13 Apr 2020 | 2,027 | 4,847 (0%) | 0% | 40.6 | 82,377 | Common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges